Phase III frontMIND Trial Shows Tafasitamab-Lenalidomide-R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas
The phase III frontMIND trial showed that adding tafasitamab and lenalidomide to R-CHOP chemotherapy reduced the risk of progression by 25% in patients with high-risk B-cell lymphomas. The 3-year progression-free survival was 67.3% with the combination versus 60.7% with R-CHOP alone. A dual-targeted CD19/CD20 immunotherapy regimen has also been approved in Australia for relapsed follicular lymphoma.
Combining the targeted therapies tafasitamab and lenalidomide with standard R-CHOP chemotherapy significantly improved progression-free survival in patients with newly diagnosed high-risk B-cell lymphomas, according to results from the phase III frontMIND trial presented at the American Society of Clinical Oncology (ASCO) annual meeting.
In the trial, 899 adults with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) received either the combination regimen or R-CHOP alone for six 21-day cycles. At a median follow-up of 35.2 months, the tafasitamab-lenalidomide-R-CHOP combination reduced the risk of disease progression or death by 25% compared to R-CHOP alone (HR 0.75, 95% CI 0.59-0.96, P=0.0194). The median progression-free survival was not reached in the combination group.
The 2-year progression-free survival rate was 71.1% with the combination versus 62.9% with R-CHOP, while the 3-year rates were 67.3% and 60.7%, respectively. The trial also showed a significant improvement in event-free survival with the combination (HR 0.79, 95% CI 0.64-0.97, P=0.0260). Interim overall survival analysis showed a trend in favor of the combination (HR 0.85, 95% CI 0.63-1.14, P=0.2703).
The complete response rate was 65.2% in both treatment groups, while the overall response rate was 80.4% in the combination group versus 76.1% in the R-CHOP group. The investigators noted that the addition of tafasitamab and lenalidomide did not compromise the delivery of the R-CHOP backbone, with median relative dose intensities remaining high and similar between groups across all six cycles.
Regarding safety, the most common adverse events were cytopenias and infections. Grade 3 or higher treatment-emergent adverse events occurred in 86.7% of patients in the combination group compared to 76.1% in the R-CHOP group. Adverse events led to discontinuation of part of treatment in 25.7% of the combination group versus 17.9% of the R-CHOP group, while about 5% of patients in both groups stopped treatment entirely.
Tafasitamab is a monoclonal antibody that targets the CD-19 protein, a surface marker expressed on both normal and malignant B cells. The combination of tafasitamab and lenalidomide is already FDA-approved for relapsed or refractory DLBCL. The researchers stated that the frontMIND results suggest the combination "is a potential new standard of frontline therapy" for high-risk DLBCL or HGBL.
The findings are particularly significant because, for more than two decades, R-CHOP has been the global standard of care for newly diagnosed DLBCL, leading to cure in about 60% of patients. The investigators noted that approximately 40% of patients, especially those with high-risk disease, are not cured with first-line R-CHOP, creating a need for better treatments.
Separately, a new dual-targeted CD19 and CD20 immunotherapy regimen has been approved in Australia for patients with relapsed or refractory follicular lymphoma. This approval marks the first time this type of dual-targeted immunotherapy has been made available in Australia as a chemotherapy-free option for this incurable disease.